Latest news articles

Added 4 months ago Drug news

Additional analyses from phase III ECHELON-1 clinical trial of Adcetris in newly diagnosed advanced Hodgkin lymphoma.- Seattle Genetics.

Seattle Genetics, Inc. highlighted data from the phase III ECHELON-1 clinical trial evaluating Adcetris (brentuximab vedotin) in combination with chemotherapy...

Added 5 months ago Drug news

NICE approves use of Adcetris for Hodgkin lymphoma.- Seattle Genetics.

UK NICE has approved the use of Adcetris (brentuximab), from Seattle Genetics, for patients with Hodgkin lymphoma who do not...

Added 5 months ago Drug news

Complete response letter for BLA for biosimilar rituximab.- Sandoz.

Sandoz, a Novartis division, announced that the FDA has issued a complete response letter (CRL) regarding the Biologics Licensing Application...

Search all news articles for Hodgkin's disease

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more


Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma

This guideline discusses the investigation and management of patients of all ages with nodular lymphocyte predominant Hodgkin lymphoma...

Added 2 years ago

Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UK

Haem-onc inpatients are at risk of critical illness and should be identified early using NEWS. ICU referral should involve direct discussion between consultant haematologist and consultant intensivist.

Added 3 years ago

Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The 2014 update elaborates on two histologically distinguished entities: classical Hodgkin's lymphoma that accounts about 95% of cases and nodular lymphocyte-predominant Hodgkin's lymphoma, which represents the remainder of cases.

Added 4 years ago

Search all guidelines for Hodgkin's disease

Journal articles

Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Immune evasion is a critical mechanism of malignant cell survival, and relies in part on molecular signaling through the programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1) axis that contributes to T cell exhaustion.

Added 5 months ago

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Background: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.

Added 10 months ago

Search all journal articles for Hodgkin's disease

Clinical trials

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD...

Added 11 months ago

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as...

Added 10 years ago

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy...

Added 1 year ago

Search all clinical trials for Hodgkin's disease
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.